Clinical trial NCT06054451: Clinical Diagnosis and Pathological Spectrum of Porto-sinusoidal Vascular Disease in India
Official title: Clinical Diagnosis and Pathological Spectrum of Porto-sinusoidal Vascular Disease in India
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Portal Hypertension
Budd-Chiari Syndrome
Non-Cirrhotic Portal Hypertension
Porto-Sinusoidal Vascular Diseases
Sinusoidal Obstruction Syndrome
Veno Occlusive Disease, Hepatic
Non-Cirrhotic Portal Fibrosis
Keywords: Porto-sinusoidal vascular disease
Budd Chiari Syndrom
extrahepatic portal venous obstruction
Portal Hypertension
Non-Cirrhotic Portal Fibrosis
Lead sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh
Sponsor class: OTHER
First posted: 2023-09-26
Enrollment: 210
Sex: ALL
Minimum age (years): 12
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients diagnosed as NCPF, EHPVO, HVOTO, SOS, VOD will be screened for reclassification based on diagnostic criteria for PSVD

Brief summary: There is a need to re-evaluate the patients classified as NCPH and determine whether the new histological classification proposed by the VALDIG applies to the Indian scenario. We intend to identify the patient cohorts who have been diagnosed as NCPH, NCPF, EHPVO, hepatic venous outlet tract obstruction (HVOTO), Veno-occlusive disease (VOD) and sinusoidal obstruction syndrome (SOS) based on their liver biopsy, endoscopy, HVPG, and radiology reports. These patients will be screened to find the patients who fit the diagnosis of PSVD. It is important to establish whether the new definition of PSVD is relevant to the Indian population and establish the usefulness of invasive tests like liver biopsy in diagnosing the disease. The patient cohorts meeting diagnosis of INCPH will be compared with those meeting the new diagnosis of PSVD. The investigators will describe the clinical (demographic, clinical risk factors, socioeconomic status), etiological (associated conditions, coagulation disorders medication use, genetic risk factors), imaging (based on ultrasound Doppler imaging or cross- sectional imaging), endoscopic, fibrosis tests (using non-invasive tests), and the histopathology of the patients who fulfil the criteria of PSVD.

Detailed description: Portal hypertension is clinically characterized by a portal venous pressure gradient between the inferior vena cava and the portal vein is more than 5 mm. Liver cirrhosis remains the leading cause of portal hypertension in the western world. However, there are conditions where portal hypertension can even occur without liver cirrhosis, referred to as Noncirrhotic portal hypertension (NCPH). The term NCPH has been derived from a variety of histopathological entities such as hepatoportal sclerosis, noncirrhotic portal fibrosis, nodular regenerative hyperplasia, or incomplete septal fibrosis. In the absence of other causes of cirrhosis and portal venous thrombosis, the condition is termed idiopathic noncirrhotic portal hypertension. The histopathological findings of INCPH are not entirely specific to portal hypertension, similar changes can be seen in patients without portal hypertension. Therefore the term Porto-sinusoidal vascular disorder(PSVD) has been recently introduced to define a group of liver vessel disorders affecting the portal venules and sinusoids irrespective of the absence or presence of liver cirrhosis. This disease entity can have a varied clinical presentation and histological findings and has been associated with several immunological and systemic disorders.

Porto-sinusoidal vascular disease - Currently, for clinical practice, the VALDIG group has given a working definition for PSVD.

"Liver biopsy ≥20mm without cirrhosis with either 1 specific sign of portal hypertension OR 1 specific histological finding for PSVD" OR "Liver biopsy ≥20mm without cirrhosis with 1 sign not specific for portal hypertension AND 1 sign not specific for PSVD"

Eligibility criteria: Inclusion Criteria:

* Patients of 12-70 years, either gender with clinical, pathological radiological diagnosis of NCPH

Exclusion Criteria:

* Any patients having Cirrhosis based on clinical, pathological, or radiological diagnosis
* Any patients having active malignancy

Primary outcomes:
measure: To describe the clinical presentation of patients with a diagnosis of PSVD.
timeFrame: Day 0
Secondary outcomes:
measure: Radiological description of patients with PSVD based on CT venography
timeFrame: Day 0
measure: Radiological description of patients with PSVD based on Doppler Ultrasound
timeFrame: Day 0
measure: Histopathological features and subtypes of the PSVD spectrum in patients from India with assessment of parenchyma, vessels, portal triad and fibrosis
timeFrame: Day 0
measure: Ratio of liver stiffness and splenic stiffness using transient elastography in diagnosis of PSVD
timeFrame: Day 0
measure: Change in biomarkers like Factor VIII Ag or vWF in diagnosis of PSVD
timeFrame: Day 0
measure: Presence of varices and other endoscopic findings in patients with PSVD
timeFrame: Day 0
Other outcomes:
Locations:
city: Sector-12
country: India
facility: Dr. Madhumita Premkumar
state: Chandigarh
Study officials:
affiliation: PGIMER
name: Dr Madhumita Premkumar, DM
role: PRINCIPAL_INVESTIGATOR
References: